Komori

Financial Results Presentation for the Second Quarter of the Fiscal Year Ending March 2027

Results presentationFirst half, FY ending Mar 2027Published 2026-11-16 15:30

In the second quarter of the fiscal year ending March 2027, revenue and all profit measures exceeded the year-earlier period, reaching record highs both for the cumulative period and the quarter alone. The full-year forecast is unchanged. Secondary care is ahead of plan, while home care has experienced inventory shortages and delays in launching new products.

In short

Forecast unchanged
  • Revenue and all profit measures exceeded the year-earlier period, reaching record highs both cumulatively and for the quarter alone.
  • Secondary care exceeded plan, while some of the inventory shortage in home care was resolved, although the launch of new products was postponed to April 2027.
  • The company will expand into Nagoya and Fukuoka, strengthen the capacity to accept patients at Tokyo Hospital and Kawasaki Main Hospital, and invest in a new electronic medical records system and AI and data platforms.

What they reported

this period against the same period a year earlier, and where they now expect the year to end

Sales

¥3.4bn+11.0%vs a year earlier
H1 FY26¥3.0bnH1 FY27¥3.4bn
FY25FY26FY27 · this year112¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4+12%this yearvs same quarter last yearlast year
Sales by quarter
Period¥bn
FY25 Q11.3
FY25 Q21.3
FY25 Q31.4
FY25 Q41.3
FY26 Q11.5
FY26 Q21.6
FY26 Q31.6
FY26 Q41.5
FY27 Q11.6
last year 6.2
was 6.6
now 6.6
Full-year forecast, ¥bn±0.0% vs the old forecast
Forecast from this deck (no earlier forecast on record)
Why

The number of consultations in secondary care remained solid, diagnostic imaging cases increased slightly, and stronger sales initiatives also proved effective in home care.

二次診療:診療数が堅調に推移。画像診断サービス:診断件数は微増。在宅ケア:営業強化策が奏功し好調。
Secondary care: The number of consultations remained solid. Diagnostic imaging services: The number of diagnostic cases increased slightly. Home care: Stronger sales initiatives proved effective, resulting in solid performance.
Bright spot

Quarterly revenue and cumulative revenue for the second quarter reached record highs.

四半期売上高は過去最高。Q2累計実績としても売上高・各利益で過去最高を更新(3期連続)
Quarterly revenue reached a record high. Cumulative second-quarter revenue and all profit measures also reached record highs, marking the third consecutive period.

Operating profit

¥0.7bn+22.7%vs a year earlier
H1 FY26¥0.6bnH1 FY27¥0.7bn
FY25FY26FY27 · this year000¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4+35%this yearvs same quarter last yearlast year
Operating profit by quarter
Period¥bn
FY25 Q10.1
FY25 Q20.2
FY25 Q30.2
FY25 Q40.1
FY26 Q10.3
FY26 Q20.3
FY26 Q30.4
FY26 Q40.2
FY27 Q10.3
last year 1.2
was 1.3
now 1.3
Full-year forecast, ¥bn±0.0% vs the old forecast
Forecast from this deck (no earlier forecast on record)
Why

In addition to the effect of higher revenue, the previous fiscal year's price revisions and productivity improvements boosted profits.

各利益:増収効果に加え、前年度に実施した価格改定効果や継続的な生産性向上の取り組み等が寄与。
All profit measures: In addition to the effect of higher revenue, the effects of the price revisions implemented in the previous fiscal year and ongoing productivity improvement initiatives, among other factors, contributed.

Ordinary profit

¥0.7bn+21.1%vs a year earlier
H1 FY26¥0.6bnH1 FY27¥0.7bn
FY25FY26FY27 · this year000¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4+34%this yearvs same quarter last yearlast year
Ordinary profit by quarter
Period¥bn
FY25 Q10.2
FY25 Q20.2
FY25 Q30.2
FY25 Q40.1
FY26 Q10.3
FY26 Q20.3
FY26 Q30.4
FY26 Q40.2
FY27 Q10.3
last year 1.1
now 1.2
Full-year forecast, ¥bnthe first forecast for this year
Forecast from this deck (no earlier forecast on record)
Why

The effect of higher revenue, price revisions, and productivity improvement initiatives, among other factors, contributed to all profit measures.

各利益:増収効果に加え、前年度に実施した価格改定効果や継続的な生産性向上の取り組み等が寄与。
All profit measures: In addition to the effect of higher revenue, the effects of the price revisions implemented in the previous fiscal year and ongoing productivity improvement initiatives, among other factors, contributed.

Net profit

¥489.0m+18.4%vs a year earlier
H1 FY26¥413.0mH1 FY27¥489.0m
FY25FY26FY27 · this year100200¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4+33%this yearvs same quarter last yearlast year
Net profit by quarter
Period¥m
FY25 Q1103.0
FY25 Q2139.0
FY25 Q3167.0
FY25 Q4111.0
FY26 Q1180.0
FY26 Q2233.0
FY26 Q3262.0
FY26 Q4158.0
FY27 Q1239.0
last year 833.0
was 890.0
now 890.0
Full-year forecast, ¥m±0.0% vs the old forecast
Forecast from this deck (no earlier forecast on record)
Why

The effect of higher revenue, price revisions, and productivity improvement initiatives, among other factors, contributed to all profit measures.

各利益:増収効果に加え、前年度に実施した価格改定効果や継続的な生産性向上の取り組み等が寄与。
All profit measures: In addition to the effect of higher revenue, the effects of the price revisions implemented in the previous fiscal year and ongoing productivity improvement initiatives, among other factors, contributed.

Their own numbers

figures this company chose to report, a year ago against now
Number of initial consultations
5,978 transactions · a year ago 5,519 transactions

The cumulative number of initial consultations in the second quarter was 5,978, representing progress of 51.5% against the full-year plan.

Number of initial consultations
11,604 transactionsFY27 plan · FY26 10,953 transactions

The full-year plan calls for 11,604 initial consultations.

Number of affiliated hospitals
4,842 facilities

The number of affiliated hospitals increased by 126 from the year-earlier period, bringing the affiliated hospital ratio to 37.1%.

Affiliated hospital ratio
37.1 %

The affiliated hospital ratio rose to 37.1%.

Number of veterinarians providing secondary care
107 people

The number of veterinarians in secondary care increased by 7 from the end of the previous fiscal year.

EBITDA+11.0%
¥1.0bn · a year ago ¥0.9bn

EBITDA increased 11.0% year on year.

The low–high ranges are Komori's estimate, not figures the company gave.

Everything else in the deck

What moved

change vs a year earlier, by the company's own breakdown
Operating income
Revenue growth+¥333.0m
Personnel expenses−¥145.0m
Facilities and IT−¥61.0m
Depreciation and amortization+¥43.0m
Other−¥35.0m
Bar colour is the direction of the amount (red = up, teal = down).

New initiatives

what they said they're starting
  • The company will acquire the land and buildings adjacent to Tokyo Hospital and strengthen the patient-acceptance capacity of Tokyo Hospital and Kawasaki Main Hospital.
  • Construction is scheduled to begin in April 2027 for the renovation of Nagoya Hospital.
  • A next-generation electronic medical records system with enhanced security will be brought into operation in stages from autumn 2027.
  • The company will consider developing services including AI diagnostic imaging, AI-assisted medical care, and AI-powered automatic entry into electronic medical records.
  • The company will deploy an integrated CRM across the group and promote joint sales activities.
  • JARMeC Care Tech will proceed with demonstrations of new products and automated vital-sign monitoring.

What decks usually leave out

COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deck

Margins and overheads

where each ¥100 of sales goes
Computed
a year ago¥19.5 profit per ¥100
60.1
20.4
19.5
now¥21.5 profit per ¥100
57.2
21.3
21.5
Cost of making itOverheads (selling, admin)Operating profit
Gross margin
39.9% → 42.8% +2.9 pts
Operating margin
19.5% → 21.5% +2.0 pts

Overheads (selling and admin costs): ¥714.0m

Financial targets

the last five years against the target (green band), where one is stated
Computed
Return on equity18.5%
profit earned on shareholders' money
14% or higher
in the target zone
7%14%20%targetFY22FY23FY24FY25FY26FY22: 11.8%FY23: 12.2%FY24: 9.0%FY25: 13.1%FY26: 18.5%18.5%
Return on equity
Period%
FY2211.8
FY2312.2
FY249.0
FY2513.1
FY2618.5
Equity ratio43.1%
how much of the balance sheet is owned outright
−4.3 pts on last year
34%42%49%FY22FY23FY24FY25FY26FY22: 36.0%FY23: 43.2%FY24: 43.5%FY25: 47.4%FY26: 43.1%43.1%
Equity ratio
Period%
FY2236.0
FY2343.2
FY2443.5
FY2547.4
FY2643.1
Payout ratio18.9%
share of profit paid as dividends
−0.7 pts on last year
-2%10%22%FY22FY23FY24FY25FY26FY27FY22: 0.0%FY23: 0.0%FY24: 16.0%FY25: 19.4%FY26: 19.6%FY27: 18.9% (forecast)18.9%
Payout ratio
Period%
FY220.0
FY230.0
FY2416.0
FY2519.4
FY2619.6
FY2718.9

Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.

How they rate themselves against plan

the company's own grade for the period, next to the numbers
What they said
Above plan

Revenue and all profit measures have been tracking above expectations, and secondary care is ahead of plan.

売上高・各利益は想定を上回って推移。 • 二次診療は計画を上回って推移、画像診断はほぼ計画どおり。
Revenue and all profit measures have been tracking above expectations. • Secondary care has been tracking ahead of plan, while diagnostic imaging has been broadly in line with plan.

Mid-term plan targets

Medium-term management plan · to 2027
Hospital revenueFinal year¥4.9bn
Consolidated net salesFinal year¥6.6bn
Consolidated operating profitFinal year¥1.3bn
ROEFinal year17%

Store or site count

Number of hospitals
4
there a year agonew this yearlost

Market size and share

square area = market size · a year ago outlined, now filled
Affiliated hospital ratio among companion-animal veterinary clinics
The number of affiliated hospitals was 4,842.
their share
36.6% → 37.1%
+0.50 pts

The company's slice (blue) is drawn magnified so a small share stays visible; compare it with its own dashed outline from a year ago.

Not mentioned in this deck

10
By businessCapital spendingShare buybackDividendForecast assumptionsRisks priced into the forecastOrders and backlogPrice and volumeHeadcountInvestor Q&A
Financial Results Presentation for the Second Quarter of the Fiscal Year Ending March 2027 | Japan Animal Referral Medical Center Co.,Ltd. (6039) timely disclosure | Komori